Abemaciclib clinical trials
Also written LY2835219 and Verzenio.
ClinicalTrials.gov finds 297 studies for abemaciclib. How that becomes 157 here
Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives abemaciclib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count
- 297Found by its intervention search · See all 297 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 246 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- 297Give abemaciclib to participants
- −36Observe patients on it, or give it outside a trial
- −4Use it as a tool: an imaging tracer or a test of drug response
- −8Compare another treatment with it
- −92Give it beside what is tested
- 157Test it: the count on this site
Get an email when these change. Save the abemaciclib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Sept 2017 · VERZENIO · NDA 208716 (FDA, Drugs@FDA)
- European Union
- 26 Sept 2018 · Verzenios · EMEA/H/C/004302 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
157 studies that test it; most in 2020 (21)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 3 |
| 2014 | 9 |
| 2015 | 8 |
| 2016 | 12 |
| 2017 | 11 |
| 2018 | 6 |
| 2019 | 19 |
| 2020 | 21 |
| 2021 | 21 |
| 2022 | 6 |
| 2023 | 8 |
| 2024 | 12 |
| 2025 | 8 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 50 · Other 107
Eli Lilly and Company (49) · Dana-Farber Cancer Institute (11) · Memorial Sloan Kettering Cancer Center (7) · National Cancer Institute (NCI) (6) · Fudan University (3) · Alliance for Clinical Trials in Oncology (2) · University of Washington (2) · OHSU Knight Cancer Institute (2)
Often tested with
Tested in the same studies.
Letrozole (10) · Fulvestrant (7) · Anastrozole (6) · Temozolomide (5) · Palbociclib (5) · Ribociclib (4) · Aromatase inhibitors (4) · Ramucirumab (3)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Abemaciclib is the comparator. A study of two new drugs counts under both.
- 1Atirmociclib · Pfizer · next primary completion Jan 2029
- 1CDK4 Inhibitor BGB-43395 · BeOne Medicines · next primary completion Apr 2029
New treatments tested with it · 8 most studied
New when their studies opened, with abemaciclib beside them; studies of each.
Reaching primary completion within a year · 28, 1 in phase 3
Studies that test abemaciclib, phase 3 first.
- Feb 2027Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant AbemaciclibPhase 3 · Fudan University
- Nov 2026A Study of Abemaciclib (LY2835219) in Healthy ParticipantsPhase 1 · Eli Lilly and Company
- Dec 2026Abemaciclib and Letrozole to Treat Endometrial CancerPhase 2 · Gynecologic Oncology Group
- Dec 2026Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerPhase 2 · The Methodist Hospital Research Institute
- Jan 2027A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisPhase 1 · Memorial Sloan Kettering Cancer Center
- Jan 2027Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6Phase 2 · Dana-Farber Cancer Institute
- Jan 2027Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast CancerPhase 2 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Jan 2027Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaPhase 1/2 · National Cancer Institute (NCI)
- Feb 2027A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyPhase 2 · Eli Lilly and Company
- Feb 2027A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)Phase 1/2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses abemaciclib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 157
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerNot yet recruitingPhase 2Eli Lilly and CompanyNCT07935317Written as AbemaciclibReport a problem
- Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasRecruitingPhase 1/2National Cancer Institute (NCI)NCT04750928Alone in NF1-related atypical neurofibromasWritten as AbemaciclibReport a problem
- Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)RecruitingPhase 4University of Illinois ChicagoNCT06169371Dose escalation to keep adjuvant dose intensityWritten as AbemaciclibReport a problem
- Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04633239Added to olaparib in recurrent ovarian cancerWritten as AbemaciclibReport a problem
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT02523014Alone in one gene-matched meningioma armWritten as AbemaciclibReport a problem
- A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06835972With cabozantinib in kidney cancerWritten as AbemaciclibReport a problem
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT06498648Added to gemcitabine against gemcitabine-docetaxel in sarcomaWritten as AbemaciclibReport a problem
- Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT04941274Alone in Kaposi sarcomaWritten as AbemaciclibReport a problem
- Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.RecruitingPhase 2City of Hope Medical CenterNCT04305834Alone or with endocrine therapy in women 70 and olderWritten as AbemaciclibReport a problem
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584With anastrozole and fulvestrantWritten as AbemaciclibReport a problem
- Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06654037Added to fluorouracil in metastatic cancerWritten as AbemaciclibReport a problem
- ALPINE: Maintenance Letrozole/AbemaciclibRecruitingPhase 2Dana-Farber Cancer InstituteNCT06366347With letrozole as maintenance in endometrial cancerWritten as AbemaciclibReport a problem
- SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT04923542With radiosurgery for brain metastasesWritten as AbemaciclibReport a problem
- A Study of Abemaciclib (LY2835219) in Healthy ParticipantsRecruitingPhase 1Eli Lilly and CompanyNCT07818967Formulations in healthy volunteersWritten as Abemaciclib Tablet (Test Formulation)Report a problem
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227With imlunestrant and selinexor in ovarian and endometrial cancerWritten as AbemaciclibReport a problem
- Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07340541With a SERD in one biomarker-driven armReport a problem
- A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for LiposarcomasRecruitingPhase 1University of WashingtonNCT06025747With radiation before surgery for liposarcomaWritten as AbemaciclibReport a problem
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498One CDK4/6 option added to elacestrantWritten as elacestrant, palbociclib, abemaciclib, ribociclibReport a problem
- A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05714072With ruxolitinib in myelofibrosisWritten as AbemaciclibReport a problem
- ETHAN - ET for Male BCRecruitingPhase 2Jose Pablo LeoneNCT05501704Added to endocrine therapy before surgery in menWritten as AbemaciclibReport a problem
See all 157 studies that test abemaciclib →
Behind its US label · 4 — the studies the FDA label of VERZENIO describes
From the Clinical Studies section of VERZENIO (2026-07), as openFDA has it. A study the site does not hold is left out.
- A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has SpreadCompletedPhase 2Eli Lilly and CompanyNCT02102490Report a problem
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT02107703Report a problem
- A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT02246621Report a problem
- Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT03155997Report a problem
Tested on its own · 45 — no other medicine in its arm
- Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasRecruitingPhase 1/2National Cancer Institute (NCI)NCT04750928Alone in NF1-related atypical neurofibromasWritten as AbemaciclibReport a problem
- Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)RecruitingPhase 4University of Illinois ChicagoNCT06169371Dose escalation to keep adjuvant dose intensityWritten as AbemaciclibReport a problem
- Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT04941274Alone in Kaposi sarcomaWritten as AbemaciclibReport a problem
- Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.RecruitingPhase 2City of Hope Medical CenterNCT04305834Alone or with endocrine therapy in women 70 and olderWritten as AbemaciclibReport a problem
- A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for LiposarcomasRecruitingPhase 1University of WashingtonNCT06025747With radiation before surgery for liposarcomaWritten as AbemaciclibReport a problem
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway AlterationRecruitingPhase 2Medical College of WisconsinNCT04040205Alone in sarcomas with CDK pathway changesWritten as AbemaciclibReport a problem
- Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast CancerNot yet recruitingPhase 4Poitiers University HospitalNCT07490509Drug levels against severe diarrhoeaReport a problem
- A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT06678269Dose finding with radiation in metastatic breast cancerWritten as AbemaciclibReport a problem
- Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6RecruitingPhase 2Dana-Farber Cancer InstituteNCT03310879Alone in tumours with cyclin D or CDK4/6 changesWritten as AbemaciclibReport a problem
- Abemaciclib in Newly Diagnosed Meningioma PatientsRecruitingPhase 2Nader SanaiNCT05940493Against placebo in newly diagnosed meningiomaWritten as AbemaciclibReport a problem
- Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibNot yet recruitingPhase 2Mario Negri Institute for Pharmacological ResearchNCT07428018With endocrine therapy before surgery, chosen by Oncotype DXWritten as AbemaciclibReport a problem
- Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast CancerNot yet recruitingPhase 2Nagoya City UniversityNCT07292207Against residual disease found by ctDNAWritten as Abemaciclib 150 MG Oral TabletReport a problem
- Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerTerminatedPhase 2Mayo ClinicNCT03979508Alone after chemotherapy-resistant triple-negative breast cancerWritten as AbemaciclibReport a problem
- (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial CancerActive, not recruitingEarly Phase 1Weill Medical College of Cornell UniversityNCT03837821Short course before surgery for bladder cancerWritten as AbemaciclibReport a problem
- SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated LiposarcomaActive, not recruitingPhase 3Sarcoma Alliance for Research through CollaborationNCT04967521Against placebo in dedifferentiated liposarcoma (SARC041)Written as AbemaciclibReport a problem
- Abemaciclib in Patients With OligodendrogliomaCompletedPhase 2Stephen Bagley, MD, MSCENCT03969706Alone in recurrent oligodendrogliomaWritten as Abemaciclib 200 MGReport a problem
- A Study of Abemaciclib in Recurrent GlioblastomaActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02981940Alone in recurrent glioblastoma, with or without surgeryWritten as AbemaciclibReport a problem
- Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain TumorsActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03220646Alone in recurrent brain tumoursWritten as abemaciclibReport a problem
- Study of Abemaciclib in Dedifferentiated LiposarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02846987Alone in dedifferentiated liposarcomaWritten as AbemaciclibReport a problem
- Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)TerminatedPhase 2University of ArizonaNCT04169074Short course before surgery for head and neck cancerWritten as AbemaciclibReport a problem
Showing 20 of 45. See all 45 →
Tested with established drugs · 29 — they are given beside it
- Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingPhase 1National Cancer Institute (NCI)NCT04633239Added to olaparib in recurrent ovarian cancerWritten as AbemaciclibReport a problem
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT06498648Added to gemcitabine against gemcitabine-docetaxel in sarcomaWritten as AbemaciclibReport a problem
- Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerEnrolling by invitationPhase 2Fudan UniversityNCT07441369With FOLFOX or FOLFIRI in colorectal liver metastasesWritten as AbemaciclibReport a problem
- Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT04469764Alone in recurrent ovarian or endometrial cancerWritten as AbemaciclibReport a problem
- ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast CancerRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT04523857Alone or with hydroxychloroquine against residual diseaseWritten as AbemaciclibReport a problem
- Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)RecruitingPhase 3Japanese Foundation for Cancer ResearchNCT07190443Added to endocrine therapy after locoregional recurrence (JCOG2313)Written as Endocrine therapy + AbemaciclibReport a problem
- A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast CancerCompletedPhase 2Eli Lilly and CompanyNCT02747004Alone or with tamoxifen (nextMONARCH)Written as AbemaciclibReport a problem
- A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT02107703On the US labelAdded to fulvestrant against placebo (MONARCH 2)Written as AbemaciclibReport a problem
- Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT05169567Added to fulvestrant after a CDK4/6 inhibitor (postMONARCH)Written as AbemaciclibReport a problem
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerActive, not recruitingPhase 2/3Eli Lilly and CompanyNCT03706365Added to abiraterone against placebo (CYCLONE 2)Written as AbemaciclibReport a problem
- A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyActive, not recruitingPhase 2Eli Lilly and CompanyNCT06413706Added to temozolomide in young patients with high-grade gliomaWritten as AbemaciclibReport a problem
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT06001762Dose escalation to ease side effects (TRADE)Written as AbemaciclibReport a problem
- A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)Active, not recruitingPhase 3Eli Lilly and CompanyNCT05288166Added to abiraterone in hormone-sensitive prostate cancer (CYCLONE 3)Written as AbemaciclibReport a problem
- Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT03155997On the US labelAdded to adjuvant endocrine therapy (monarchE)Written as AbemaciclibReport a problem
- A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT02246621On the US labelAdded to an aromatase inhibitor against placebo (MONARCH 3)Written as AbemaciclibReport a problem
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingPhase 1Eli Lilly and CompanyNCT02057133Added to endocrine or HER2 therapies, early dosingWritten as LY2835219Report a problem
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT02779751With pembrolizumab in lung and breast cancerWritten as AbemaciclibReport a problem
- PreOperative Endocrine Therapy for Individualised Care With AbemaciclibActive, not recruitingPhase 3Institute of Cancer Research, United KingdomNCT04584853Added to endocrine therapy before surgery (POETIC-A)Written as AbemaciclibReport a problem
- ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaLCompletedPhase 2MedSIRNCT04603183With endocrine therapy against paclitaxel in aggressive diseaseWritten as AbemaciclibReport a problem
- A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast CancerTerminatedPhase 3Eli Lilly and CompanyNCT04752332Added to adjuvant endocrine therapy against placeboWritten as AbemaciclibReport a problem
Showing 20 of 29. See all 29 →
Tested in a combination · 83 — another drug in the study is under test too
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerNot yet recruitingPhase 2Eli Lilly and CompanyNCT07935317Written as AbemaciclibReport a problem
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT02523014Alone in one gene-matched meningioma armWritten as AbemaciclibReport a problem
- A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06835972With cabozantinib in kidney cancerWritten as AbemaciclibReport a problem
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584With anastrozole and fulvestrantWritten as AbemaciclibReport a problem
- Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06654037Added to fluorouracil in metastatic cancerWritten as AbemaciclibReport a problem
- ALPINE: Maintenance Letrozole/AbemaciclibRecruitingPhase 2Dana-Farber Cancer InstituteNCT06366347With letrozole as maintenance in endometrial cancerWritten as AbemaciclibReport a problem
- SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT04923542With radiosurgery for brain metastasesWritten as AbemaciclibReport a problem
- A Study of Abemaciclib (LY2835219) in Healthy ParticipantsRecruitingPhase 1Eli Lilly and CompanyNCT07818967Formulations in healthy volunteersWritten as Abemaciclib Tablet (Test Formulation)Report a problem
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227With imlunestrant and selinexor in ovarian and endometrial cancerWritten as AbemaciclibReport a problem
- Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07340541With a SERD in one biomarker-driven armReport a problem
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingPhase 2Northwestern UniversityNCT06062498One CDK4/6 option added to elacestrantWritten as elacestrant, palbociclib, abemaciclib, ribociclibReport a problem
- A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05714072With ruxolitinib in myelofibrosisWritten as AbemaciclibReport a problem
- ETHAN - ET for Male BCRecruitingPhase 2Jose Pablo LeoneNCT05501704Added to endocrine therapy before surgery in menWritten as AbemaciclibReport a problem
- Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07191717With imlunestrant against residual diseaseWritten as AbemaciclibReport a problem
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)RecruitingPhase 2David Reardon, MDNCT02977780With temozolomide in one glioblastoma armWritten as AbemaciclibReport a problem
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingPhase 2Eli Lilly and CompanyNCT05999994In one sub-study of a paediatric master protocolWritten as AbemaciclibReport a problem
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate CancerRecruitingPhase 1/2Vadim S KoshkinNCT05113537Before lutetium-177 PSMA-617 in prostate cancerWritten as AbemaciclibReport a problem
- A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07209449With elacestrant in endometrial cancerWritten as AbemaciclibReport a problem
- RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT03675893With letrozole in endometrial cancer; metformin or gedatolisib addedWritten as AbemaciclibReport a problem
- Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant AbemaciclibRecruitingPhase 2University of Texas Southwestern Medical CenterNCT04614194Added to letrozole before surgery, immune correlatesWritten as AbemaciclibReport a problem
Showing 20 of 83. See all 83 →
Beside an established treatment under test · 5 — an approved drug, surgery or radiation is what the study tests
Tested with abemaciclib: copanlisib hydrochloride 1 · Surgery or a procedure 1 · palbociclib 1 · ribociclib 1 · Anastrozole 1 · exemestane 1 · Radiation 1 · Hydroxychloroquine 1
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 3Fudan UniversityNCT07005557One CDK4/6 option, chemotherapy-free against chemotherapyReport a problem
- Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast CancerRecruitingNot applicableCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06197581One CDK4/6 option beside concurrent radiotherapyReport a problem
- Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03939897In every armUsual treatment with fulvestrant while copanlisib is addedWritten as AbemaciclibReport a problem
- Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast CancerWithdrawnPhase 1Medical College of WisconsinNCT04316169In every armTaken with endocrine therapy while hydroxychloroquine is addedWritten as AbemaciclibReport a problem
- Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesWithdrawnPhase 1Emory UniversityNCT04585724One CDK4/6 option while radiosurgery is studiedWritten as AbemaciclibReport a problem
Beside a new treatment under test · 56 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with abemaciclib: giredestrant 5 · inavolisib 5 · LY3214996 4 · ipatasertib 4 · vepdegestrant 2 · AZD9833 2 · capivasertib 2 · Imlunestrant 2
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationRecruitingPhase 3LeonaBioNCT05696626In every armPartner of new lasofoxifene against fulvestrant (ELAINE-3)Written as Lasofoxifene in combination with abemaciclibReport a problem
- Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsRecruitingPhase 1National Cancer Institute (NCI)NCT05372640In every armPartner of new ZEN-3694Written as AbemaciclibReport a problem
- A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast CancerRecruitingPhase 1Prelude Therapeutics IncorporatedNCT07905001Partner of new PRT13722 with fulvestrantWritten as AbemaciclibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Partner of new inavolisib in some armsWritten as AbemaciclibReport a problem
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingPhase 1Eli Lilly and CompanyNCT07114601One standard partner of new LY4257496Report a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Partner of new giredestrant in an umbrella cohortWritten as AbemaciclibReport a problem
- A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast CancerRecruitingPhase 2University of WashingtonNCT07112053Partner of the new STEMVAC vaccineWritten as AbemaciclibReport a problem
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossRecruitingPhase 1/2Tango Therapeutics, Inc.NCT06810544Partner of new TNG456Written as abemaciclibReport a problem
- A Study to Evaluate ATX-898 in Participants With Advanced Solid TumorsRecruitingPhase 1/2Antares Therapeutics, IncNCT07767474Partner of new ATX-898 with fulvestrantReport a problem
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingPhase 1/2Stemline Therapeutics, Inc.NCT05386108In every armPartner of new elacestrant in brain metastasesWritten as AbemaciclibReport a problem
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Avenzo Therapeutics, Inc.NCT05867251Partner of new AVZO-021Written as AbemaciclibReport a problem
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingPhase 1/2Michael J. Dennis, MDNCT05774899Partner of new CB-103 in adenoid cystic carcinomaWritten as AbemaciclibReport a problem
- Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.Not yet recruitingPhase 3UNICANCERNCT07717450Partner of new camizestrant in the ctDNA-guided switch armReport a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Partner of new tersolisibWritten as AbemaciclibReport a problem
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingPhase 1/2Ellipses PharmaNCT05573126Partner of new EP0062 in one moduleWritten as AbemaciclibReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Partner of new oral SERDs in endocrine pilot armsWritten as Amcenestrant + AbemaciclibReport a problem
- VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingPhase 1/2Adrienne G. WaksNCT05608252In every armPartner of new avutometinib with fulvestrantWritten as AbemaciclibReport a problem
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerRecruitingPhase 1/2Incyclix BioNCT05735080Partner of new INX-315 in one partWritten as AbemaciclibReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352Partner of new giredestrant in one cohortWritten as AbemaciclibReport a problem
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingPhase 1/2Forward Pharmaceuticals Co., Ltd.NCT07002177Partner of new FWD1802Written as Abemaciclib 150 MGReport a problem
Showing 20 of 56. See all 56 →
Beside supportive care · 8 — a supportive treatment or test is studied
- IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCERecruitingNot applicableInstitut fuer FrauengesundheitNCT07521202Adjuvant treatment while patient coaching is testedReport a problem
- Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer TreatmentRecruitingNot applicableUniversity of ChicagoNCT07553234Treatment while a gut health intervention is testedReport a problem
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303In every armTreatment whose response FFNP-PET imaging predictsWritten as AbemaciclibReport a problem
- Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)RecruitingNot applicableInstitut CurieNCT07491380Treatment while capillary drug monitoring is testedReport a problem
- Probiotics for Abemaciclib-Induced Abdominal Discomfort.RecruitingPhase 2Leeuwenhoek Laboratories Co. Ltd.NCT07605728Treatment whose abdominal discomfort probiotics may easeReport a problem
- Gut Microbiome Changes During Abemaciclib Therapy in Breast CancerNot yet recruitingNot applicableUniversity of Vermont Medical CenterNCT07406594Treatment whose gut microbiome potato starch may changeReport a problem
- Immunomonitoring of Breast Cancer Patients During Systemic TreatmentRecruitingNot applicableCentre Georges Francois LeclercNCT04925856Treatment during which immune cells are monitoredReport a problem
- Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast CancerStatus unknownPhase 3Henrik LindmanNCT06152471Treatment whose gut side effects Salovum and SPC-Flakes treatReport a problem
One option of several · 23 — a test or a strategy chooses among drugs
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One matched drug in a national access studyWritten as AbemaciclibReport a problem
- Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerRecruitingNot applicableNatera, Inc.NCT07214532One CDK4/6 option started on a positive ctDNA testReport a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336In every armOne CDK4/6 option while new tersolisib is addedWritten as AbemaciclibReport a problem
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751One CDK4/6 option beside new saruparib and camizestrantWritten as AbemaciclibReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535One approved drug matched to tumour geneticsWritten as Abemaciclib (CLOSED TO ENROLLMENT)Report a problem
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07826052One CDK4/6 option, chemotherapy exemption in older womenReport a problem
- Novel Molecular Targets and Innovative Therapeutic Perspective in MedulloblastomaRecruitingEarly Phase 1Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06959979One CDK4/6 option in medulloblastomaReport a problem
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07782840In every armOne CDK4/6 option beside new QL1706Written as CDK4/6 inhibitorReport a problem
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079In every armOne drug chosen by patient-derived organoidsWritten as AbemaciclibReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One option in molecular-typed salivary treatmentReport a problem
- Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06409390In every armOne drug in an evolution-guided sequenceWritten as AbemaciclibReport a problem
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsRecruitingPhase 3Region Örebro CountyNCT06044623One CDK4/6 option, lower starting dose in older patientsReport a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234One matched drug in DRUPWritten as AbemaciclibReport a problem
- Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast CancerRecruitingNot applicableCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05345860One adjuvant option; a residual-disease strategy is studiedReport a problem
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingPhase 3AstraZenecaNCT04964934In every armOne CDK4/6 option while new camizestrant is switched to (SERENA-6)Written as AbemaciclibReport a problem
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748In every armOne CDK4/6 option while new giredestrant replaces fulvestrantWritten as AbemaciclibReport a problem
- Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerActive, not recruitingPhase 3Borstkanker Onderzoek GroepNCT03425838One CDK4/6 option, first against second line (SONIA)Report a problem
- Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionActive, not recruitingPhase 2Royal Marsden NHS Foundation TrustNCT04920708One standard option in the observational armsReport a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingPhase 2University of MiamiNCT05826964One switch option guided by blood DNAReport a problem
- Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast CancerActive, not recruitingPhase 2Xinhong Wu, PhDNCT07130643One CDK4/6 option with endocrine therapy before surgeryReport a problem
Showing 20 of 23. See all 23 →
As the comparator · 8 — what is tested is compared with abemaciclib
- Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNot applicableHenan Cancer HospitalNCT07706933One comparator choice for dalpiciclibWritten as Abemaciclib/RibociclibReport a problem
- A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruitingPhase 1/2Genentech, Inc.NCT07100106Comparator with giredestrant for new GDC-4198Written as AbemaciclibReport a problem
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruitingPhase 3BeOne MedicinesNCT07492641One comparator choice for new BGB-43395Written as AbemaciclibReport a problem
- Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeRecruitingPhase 2MedSIRNCT06486883One CDK4/6 option in the comparator against T-DXdReport a problem
- A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCRecruitingPhase 2National Taiwan University HospitalNCT05766410Comparator for palbociclib, immune effects comparedWritten as AbemaciclibReport a problem
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingPhase 3PfizerNCT06760637One investigator's-choice comparator for new atirmociclibWritten as abemaciclibReport a problem
- A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast CancerWithdrawnPhase 3Danish Breast Cancer Cooperative GroupNCT06585969One CDK4/6 option in the comparator against T-DXdWritten as Abemaciclib with ETReport a problem
- CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDOCompletedPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT03227328One CDK4/6 option in the comparator against chemotherapyReport a problem
Observed · 36 — patients on it are followed, or it is given outside a trial
- Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast CancerRecruitingInstitut fuer FrauengesundheitNCT07531693Persistence on adjuvant treatment at six monthsReport a problem
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingFundación Santa Fe de BogotaNCT07856225Among CDK4/6 inhibitors, by molecular subtypeReport a problem
- To Identify Primary Resistance to CDK4/6 Inhibitors in Breast CancerRecruitingFondazione Sandro PitiglianiNCT04660435Among CDK4/6 inhibitors, primary resistanceReport a problem
- A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceRecruitingNovartis PharmaceuticalsNCT06830720One comparison cohort beside ribociclib in practiceReport a problem
- Real-world Data in Patients With Breast Cancer Treated With AbemaciclibRecruitingHellenic Cooperative Oncology GroupNCT04985058Real-world use with endocrine therapy in GreeceReport a problem
- Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.RecruitingNovartis PharmaceuticalsNCT07243002One comparison cohort beside ribociclib early adoptersReport a problem
- DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsRecruitingMayo ClinicNCT06388122A biomarker assay in patients starting CDK4/6 treatmentReport a problem
- Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without DiarrheaRecruitingHubei Cancer HospitalNCT07264998Gut microbiota and diarrhoea on treatmentReport a problem
- Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast CancerRecruitingInstitute of Oncology LjubljanaNCT06650423Adherence with aromatase inhibitors in early breast cancerReport a problem
- Real-world Studies of CDK4/6 InhibitorsRecruitingTianjin Medical University Cancer Institute and HospitalNCT07407439Real-world use in ChinaReport a problem
- Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast CancerRecruitingWenjin YinNCT07180056Adjuvant CDK4/6 useReport a problem
- Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer PatientsRecruitingAzienda Ospedaliero-Universitaria di ModenaNCT07151911Among adjuvant breast cancer treatments in practiceWritten as abemaciclib, olaparib and endocrine therapyReport a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingFondazione Policlinico Universitario Campus Bio-MedicoNCT07021911One treatment group in a radiotherapy studyReport a problem
- Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyRecruitingFondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT06805812Among CDK4/6 inhibitors, outcomes predictedWritten as AbemaciclibReport a problem
- A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 InhibitorsRecruitingCliniques universitaires Saint-Luc- Université Catholique de LouvainNCT06171360Gut microbiome during first-line CDK4/6 treatmentReport a problem
- Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)RecruitingUniversity Hospital, BrestNCT06621459Safety and side-effect management in adjuvant useReport a problem
- A Retrospective Real-world Study of Abemaciclib in HR+ Breast CancerNot yet recruitingThe Affiliated Hospital of Qingdao UniversityNCT06341283Real-world outcomes, side effects and costsWritten as Abemaciclib and Letrozole/AnastrozoleReport a problem
- A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among BreastNot yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05267327Post-marketing safety in ChinaReport a problem
- A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 InhibitorsCompletedNovartis PharmaceuticalsNCT07647042Patients eligible after adjuvant approvalReport a problem
- Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records DatabasesCompletedBrigham and Women's HospitalNCT07225790Emulating MONARCH 3 in health recordsReport a problem
Showing 20 of 36. See all 36 →
As a tool · 4 — an imaging tracer or a test of drug response
- Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerNot yet recruitingEarly Phase 1Oliver JonasNCT07892300One drug in a microdevice measuring local responseReport a problem
- Implantable Microdevice In Primary Brain TumorsRecruitingEarly Phase 1Oliver JonasNCT04135807One drug in a microdevice measuring local responseReport a problem
- Drug Screening Using Novel IMD in Renal Cell CarcinomaRecruitingPhase 1Oliver JonasNCT05700461One drug in a microdevice measuring local responseReport a problem
- Implantable Microdevice for TNBC - Pilot StudyWithdrawnPhase 1Dana-Farber Cancer InstituteNCT05774886One drug in a microdevice measuring local responseReport a problem
What changed recently
From the registry's own updates since Oct 17, 2026.
Results posted2
Codes
What other systems call abemaciclib · ClinicalTrials.gg INT000043
- MeSH (NLM) C000590451abemaciclibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 60UAB198HKABEMACICLIBConfirmed FDA, NLM, Wikidata
- RxNorm 1946825Confirmed FDA, Wikidata
- Wikidata Q23901483abemaciclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97660AbemaciclibOne source FDA
- DrugBank DB12001One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000590451 | abemaciclib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 60UAB198HK | ABEMACICLIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1946825 | — | Confirmed FDA, Wikidata |
| Wikidata | Q23901483 | abemaciclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97660 | Abemaciclib | One source FDA |
| DrugBank | DB12001 | — | One source Wikidata |
Also registered as abemaciclib mesylate (UNII KKT462Q807).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.